{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H+Cancer", "query": { "condition": "MSI-H Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 79, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=MSI-H+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T19:05:26.622Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03374254", "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-Fluorouracil [5-FU]", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2018-02-16", "completion_date": "2023-07-18", "has_results": true, "last_update_posted_date": "2024-11-21", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 10, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374254" }, { "nct_id": "NCT03607890", "title": "Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy", "MSI-H Tumors" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2018-11-16", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 2, "location_summary": "Los Angeles, California • Baltimore, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03607890" }, { "nct_id": "NCT05239546", "title": "Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "dMMR Colorectal Cancer" ], "interventions": [ { "name": "Dostarlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2023-03-24", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239546" }, { "nct_id": "NCT04417465", "title": "First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors Cancer" ], "interventions": [ { "name": "ABBV-CLS-579", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "DRUG" }, { "name": "VEGFR TKI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2020-06-03", "completion_date": "2025-08-21", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 5, "location_summary": "Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04417465" }, { "nct_id": "NCT03454243", "title": "Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "RXDX-106", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-15", "completion_date": "2018-06-05", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454243" }, { "nct_id": "NCT06898450", "title": "A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors Cancer", "MSI-H Cancer" ], "interventions": [ { "name": "NDI-219216", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nimbus Wadjet, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 134, "start_date": "2025-03-31", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Louisville, Kentucky + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Ithaca", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06898450" }, { "nct_id": "NCT04242199", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma", "Cervical Cancer", "HepatoCellular Carcinoma", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "INCB099280", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2020-09-04", "completion_date": "2024-11-21", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04242199" }, { "nct_id": "NCT04774419", "title": "Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "Intensity modulated radiation therapy (IMRT)", "type": "RADIATION" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "Hypofractionated IMRT", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 62, "start_date": "2021-04-02", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04774419" }, { "nct_id": "NCT05909995", "title": "Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Hepatocellular Carcinoma (HCC)", "Renal Cell Carcinoma (RCC)", "Microsatellite Instability - High (MSI-H)", "Mismatch Repair Deficient (dMMR)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "INCB 99280 with Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-08-29", "completion_date": "2024-11-11", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 5, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05909995" }, { "nct_id": "NCT06034860", "title": "Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Hepatocellular Carcinoma", "Melanoma", "Renal Cell Carcinoma", "Microsatellite Instability High", "Mismatch Repair Deficiency", "Mesothelioma", "Esophageal Squamous Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "MT-8421", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Templates, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-11-01", "completion_date": "2024-10-31", "has_results": false, "last_update_posted_date": "2024-11-01", "last_synced_at": "2026-06-10T19:05:26.622Z", "location_count": 5, "location_summary": "Los Angeles, California • Lafayette, Indiana • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lafayette", "state": "Indiana" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06034860" } ] }